Understanding how certain proteins affect liver and gastrointestinal cancers
Official title: Cellular interactions between TGF-beta pathway members and epigenetic regulators in liver and gastrointestinal cancers
Funded at Feinstein Institute for Medical Research · NIH-11067815 · Data updated 2026-11-12
This study is looking at how certain proteins in the liver interact with each other and how this might affect the development of liver cancer in people with a liver condition called NASH, with the hope of finding new ways to treat or prevent cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Feinstein Institute for Medical Research NIH-funded |
| Lab location | 1 site (Manhasset, United States) |
| Project start | July 18, 2018 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $418,750 |
| NIH project number | 5R01CA236591-07 |
| Project ID | NIH-11067815 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with non-alcoholic steatohepatitis (NASH) or those at risk of developing hepatocellular cancer (HCC).
✕Less likely to help
Patients with cancers unrelated to liver or gastrointestinal systems may not receive any benefit from this research.
What this research studies
This research investigates the interactions between proteins involved in the TGF-beta signaling pathway and epigenetic regulators in the context of liver and gastrointestinal cancers. It focuses on how these interactions may influence the progression of liver diseases, particularly in patients with non-alcoholic steatohepatitis (NASH) who develop hepatocellular cancer (HCC). By studying specific proteins like SIRT6 and β2-spectrin, the research aims to uncover mechanisms that could lead to new therapeutic strategies. Patients may benefit from insights that could improve treatment options or prevention strategies for liver cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatments or preventive measures for patients at risk of liver and gastrointestinal cancers.
How similar studies have gone: Other research has shown promising results in understanding the role of TGF-beta signaling in cancer, indicating that this approach has potential for success.
Where this research is happening
-
Feinstein Institute for Medical Research
Manhasset, United States Active
Researchers
- Principal investigator: Mishra, Lopa — Feinstein Institute for Medical Research
- Study coordinator: Mishra, Lopa
Related research
Other NIH-funded projects on the same topics.
-
Bacterial biosensors to detect and help prevent GI cancers
A team is building living bacterial sensors that could detect colorectal and pancreatic tumors inside the gut and give a clear diagnostic signal.
-
Gastrointestinal cancers: how stem cells and their environment shape cancer growth
A research project at Columbia University Health Sciences studies how stomach, esophagus, and other GI cancers start and evolve by looking at stem cells, nerve signals, and the surrounding tissue.
-
Bacterial biosensors to help detect GI cancers early
A living bacterial sensor is being developed to spot colorectal and pancreatic cancers early inside the GI tract and give a readable diagnostic output.
-
DPYD Genetic Testing in Community Cancer Care to Prevent Fluoropyrimidine Toxicity
A community-based study will test whether offering DPYD genetic testing before chemotherapy with FP drugs reduces severe side effects and hospitalizations for people with GI cancers.
-
Cell signaling and gene regulation in liver and gastrointestinal cancers
Researchers are looking at how signaling proteins and gene-regulating enzymes like SIRT6 interact to explain why fatty liver disease can turn into liver cancer.
-
Understanding and Improving Chemoradiation Response in Esophagogastric and Pancreatic Cancer
This grant aims to learn why esophagogastric and pancreatic cancers resist standard chemoradiation and to use that knowledge to guide better, biomarker-driven treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.